As weight loss drugs like Ozempic and Mounjaro gain a lot of attention worldwide a new study has revealed a rare side effect ...

Scholar Rock Holding Corporation (NASDAQ:SRRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Scholar Rock ...

As weight-loss drugs are gaining popularity among Indian diabetes and obesity stricken patients in India, new research highlights rare but serious eye risks linked to the blockbuster GLP-1 medications ...

Recent research suggests a possible increased risk of serious eye conditions, such as non-arteritic anterior ischaemic optic ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Obesity is a worldwide problem that is increasing. It also is associated with ocular problems. A recent study found that in ...

Overview - As demand for GLP-1 drugs continues to skyrocket, federal and state agencies are turning their attention to the GLP-1 ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 ...